Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 1414 · Expedited Access to Biosimilars Act ·

Reported by committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 262 Regulation of biological products

+24 −8Shown
More for 42 U.S.C. § 262
Read § 262Only this section
8 changes the bill asks for here, 8 carried out
  1. Carried out:

    by striking or (cc) and inserting , (cc), or (dd); and

  2. Carried out:

    by striking and at the end; and

  3. Carried out:

    by striking item (cc) and inserting the following(cc) an assessment of pharmacokinetics and immunogenicity (which may rely on, or consist of, a clinical pharmacokinetics study or studies described in item (aa) or (dd)), as appropriate; and (dd) a clinical study or studies, if required by the Secretary pursuant to clause (ii)(II), to support a demonstration that there is no clinically meaningful difference between the biological product and the reference product in terms of safety, purity, and potency of such product;; and

  4. Carried out:

    in the clause heading, by striking Determination and inserting Determinations;

  5. Carried out:

    by striking The Secretary may and inserting the following:(I) In general.— The Secretary may; and

  6. Carried out:

    by adding at the end the following:(II) Procedure for certain studies.— (aa) In general.— For an application for licensure of a biosimilar biological product submitted under this subsection, the Secretary may require a clinical study that includes an assessment of pharmacodynamics or efficacy, as described in …

  7. Carried out:

    by striking subparagraph (B); and

  8. Carried out:

    by redesignating subparagraph (C) as subparagraph (B).

§ 262(k)(2)(A)In general(i)–(iii)

Start of § 262 to (k)(2)(A)(i)(I) unchanged ·

(aa) analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components;

(bb) an assessment of toxicity (which may rely on, or consist of, a study or studies described in item (aa) [struck: or][inserted: ,] (cc)[inserted: , or (dd])[inserted: )];[struck: and]

(cc) [struck: a][inserted: an] [struck: clinical study or studies (including the ]assessment of [struck: immunogenicity][inserted: pharmacokinetics] and [struck: pharmacokinetics][inserted: immunogenicity] [struck: or][inserted: (which] [struck: pharmacodynamics)][inserted: may] [struck: that][inserted: rely] [struck: are sufficient to demonstrate safety][inserted: on], [struck: purity, and potency in 1 ]or [struck: more][inserted: consist] [struck: appropriate conditions ]of[inserted: ,] [struck: use][inserted: a] [struck: for][inserted: clinical] [struck: which][inserted: pharmacokinetics] [struck: the][inserted: study] [struck: reference][inserted: or] [struck: product][inserted: studies] [struck: is][inserted: described] [struck: licensed][inserted: in] [struck: and][inserted: item] [struck: intended][inserted: (aa)] [struck: to][inserted: or] [struck: be][inserted: (dd)),] [struck: used][inserted: as] [struck: and for which licensure is sought for the biological product][inserted: appropriate];[inserted: and]

(dd) [inserted: a clinical study or studies, if required by the Secretary pursuant to clause (ii)(II), to support a demonstration that there is no clinically meaningful difference between the biological product and the reference product in terms of safety, purity, and potency of such product;]

(II) the biological product and reference product utilize the same mechanism or mechanisms of action for the condition or conditions of use prescribed, recommended, or suggested in the proposed labeling, but only to the extent the mechanism or mechanisms of action are known for the reference product;

(III) the condition or conditions of use prescribed, recommended, or suggested in the labeling proposed for the biological product have been previously approved for the reference product;

(IV) the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product; and

(V) the facility in which the biological product is manufactured, processed, packed, or held meets standards designed to assure that the biological product continues to be safe, pure, and potent.

(ii) [struck: Determination][inserted: Determinations] by Secretary

(I) [inserted: In general.—] [inserted: The Secretary may determine, in the Secretary’s discretion, that an element described in clause (i)(I) is unnecessary in an application submitted under this subsection.]

(II) [inserted: Procedure for certain studies.—]

(aa) [inserted: In general.—] [inserted: For an application for licensure of a biosimilar biological product submitted under this subsection, the Secretary may require a clinical study that includes an assessment of pharmacodynamics or efficacy, as described in clause (i)(I)(dd), only if the Secretary provides a written determination, as described in item (bb) or (cc), to the sponsor of the biosimilar biological product that such assessments or studies are necessary, in combination with other information required pursuant to clause (i)(I), to demonstrate biosimilarity.]

(bb) [inserted: Written determination.—] [inserted: The Secretary shall—]

(AA) [inserted: when the Secretary issues meeting minutes of a biosimilar biological product development meeting (as such term is defined in section 744G(5) of the Federal Food, Drug, and Cosmetic Act), provide a written determination described in item (aa), or provide written notice to the sponsor that describes why such a determination can not be made at such time; and]

(BB) [inserted: if the Secretary is unable to make a written determination described in item (aa) at the time described in subitem (AA), provide such determination not later than 60 days after the date of submission of an application for licensure under this section.]

(cc) [inserted: Amendment to a determination.—] [inserted: A written determination under this subclause shall not be amended to require a clinical study or studies described in clause (i)(I)(dd) after the date on which such a determination is made, except—]

(AA) [inserted: by written agreement with the sponsor; or]

(BB) [inserted: in the case that the Secretary determines there is a scientific justification to amend the determination, provides a detailed written justification to the sponsor as soon as practicable, and, upon the request of the sponsor, holds a biosimilar biological product development meeting (as such term is defined in section 744G(5) of the Federal Food, Drug, and Cosmetic Act) to discuss the amendment.]

[struck: The Secretary may determine, in the Secretary’s discretion, that an element described in clause (i)(I) is unnecessary in an application submitted under this subsection.]

(iii) Additional information An application submitted under this subsection—

(I) shall include publicly-available information regarding the Secretary’s previous determination that the reference product is safe, pure, and potent;

§ 262(k)Licensure of biological products as biosimilar or interchangeable(5)–(6)

(k)(2)(A)(iii)(II)–(4)(B) unchanged ·

(5) General rules

(A) One reference product per application A biological product, in an application submitted under this subsection, may not be evaluated against more than 1 reference product.

[struck: (B)] [struck: Review] [struck: An application submitted under this subsection shall be reviewed by the division within the Food and Drug Administration that is responsible for the review and approval of the application under which the reference product is licensed.]

[struck: (C)] [inserted: (B)] Risk evaluation and mitigation strategies The authority of the Secretary with respect to risk evaluation and mitigation strategies under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] shall apply to biological products licensed under this subsection in the same manner as such authority applies to biological products licensed under subsection (a).

(6) Exclusivity for first interchangeable biological product The Secretary shall not make approval as an interchangeable biological product effective with respect to an application submitted under this subsection that relies on the same reference product for which a prior biological product has received a determination of interchangeability for any condition of use, until the earlier of—

(A) 1 year after the first commercial marketing of the first interchangeable biosimilar biological product to be approved as interchangeable for that reference product;

Rest of § 262 unchanged ·

Step through the changes